Objectives: Long non-coding RNAs (lncRNAs) are a group of non-protein-coding RNAs that are greater than 200 nucleotides in length. Increasing evidence indicates that lncRNAs, which may serve as either oncogenes or tumour suppressor genes, play a vital role in the pathophysiology of human diseases, especially in tumourigenesis and progression.
| INTRODUCTION
According to the draft of the human genome project (HGP), the human genome contains only approximately 20 000 protein-coding genes, which accounts for less than 2% of the entire genome. Generally, at least 70% of the sequences are transcribed into RNAs in higher eukaryotic genomes. To our knowledge, most of these transcripts are noncoding RNAs (ncRNAs), which were originally regarded as transcriptional noise and attracted limited attention. [1] [2] [3] [4] [5] Thanks to recent advances in sequencing technology and large-scale genome sequencing projects, both short ncRNAs (<200 nucleotides) and long ncRNAs (>200 nucleotides)
have been implicated as critical regulators in diverse human diseases.
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Long noncoding RNAs (lncRNAs), which are mainly transcribed by RNA polymerase II and lack an obvious open reading frame, are a group of ncRNAs that are greater than 200 nucleotides in length. [9] [10] [11] [12] lncRNAs can be involved in the regulation of gene expression at epigenetic, transcriptional and post-transcriptional levels. [13] [14] [15] [16] lncRNAs are widely reported to regulate pathophysiological processes by mechanisms ( Figure 1 ) such as gene imprinting, histone modification, chromatin remodelling, transcriptional activation, transcriptional interference, nuclear transport, and cell cycle regulation. [17] [18] [19] [20] [21] The recently proposed competing endogenous RNA (ceRNA) regulatory network also suggests that lncRNAs may work as sponges by binding competitively to microRNAs (miRNAs) and consequently repressing their function (ie, blocking interactions with target mRNAs). 22, 23 Multiple lncRNAs are aberrantly expressed in different disease types, particularly in refractory tumours with unclear pathogenesis. [24] [25] [26] lncRNA dysregulation generally contributes to cancer progression by promoting malignant biological behaviours in tumour cells, such as proliferation, invasion and metastasis. 27, 28 Additionally, lncRNAs may serve as potential therapeutic targets and biomarkers for diagnosis or prognosis due to high tissue specificity, high efficiency and elevated stability.
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Long noncoding RNA-activated by transforming growth factor β (lncRNA-ATB), which is located on chromosome 14, is a promising candidate among all tumour-associated lncRNAs and is overexpressed in numerous human cancers but downregulated in pancreatic cancer.
The present review summarizes current evidence regarding the abnormal expression, molecular mechanism and clinical significance of lncRNA-ATB, which is one of the most important regulatory RNAs in human cancer (Table 1 ) ( Figure 2 ).
| LNCRNA-ATB DEREGULATION IN HUMAN CANCERS

| Hepatocellular carcinoma
Hepatocellular carcinoma (HCC), which causes approximately 600 000 deaths each year, is the third leading cause of cancer deaths worldwide. Both hepatitis B and C virus infections are significant factors involved in the development of HCC. The poor prognosis and high recurrence rates are largely attributed to intrahepatic and extrahepatic metastases in early HCC. 31 Exploring the key molecular mechanisms involved in the initiation and progression of HCC is therefore required to discover novel biomarkers and therapeutic targets.
Yuan et al 32 initially demonstrated that lncRNA-ATB transcript levels were significantly increased in 86 HCC tissues compared with those in paired adjacent noncancerous hepatic tissues and were further increased in portal vein tumour thrombus. Moreover, lncRNA-ATB overexpression was significantly correlated with liver cirrhosis, microvascular invasion, encapsulation, low recurrence-free survival rate and overall survival rate. Thus, high lncRNA-ATB levels clearly promote the invasion-metastasis cascade of HCC. Hepatic fibrosis is a crucial factor in the development of liver cirrhosis, which significantly contributes to the development of HCC. 33 Fu et al 34, 35 confirmed that lncRNA-ATB was dramatically upregulated in liver tissues and plasma from patients with HCV-related fibrosis. These data suggest that lncRNA-ATB may serve as a specific biomarker and therapeutic target for HCC and liver fibrosis patients. Notably, the efficacy and therapeutic potential of ultrasound-targeted microbubble destruction-mediated siRNA transfection against lncRNA-ATB to suppress HCC migration and invasion has been reported. 
| Gastric cancer
Gastric cancer (GC) represents a major health burden worldwide, being the second main cause of cancer-related deaths. Although early treatment of GC has achieved considerable success, the long-term survival rate of GC is still low given the lack of appropriate biomarkers for early detection. Both carcinoembryonic antigen (CEA) and CA125
are frequently used as indicators in clinical practice, with dissatisfactory sensitivity and specificity, even when used in combination. 37 Therefore, identifying novel molecular abnormalities is crucial for the early diagnosis of this deadly disease.
Saito et al 38 corroborated findings that lncRNA-ATB expression levels were significantly elevated in GC tissues compared with those in adjacent nontumour tissues and closely correlated with vascular invasion and overall survival rate. Moreover, upregulated lncRNA-ATB was indicated as an independent poor prognostic factor for GC patients by multivariate analyses. Subsequently, Lei et al 39 similarly
uncovered that lncRNA-ATB was upregulated in GC tissues and that silencing lncRNA-ATB inhibited proliferation in vitro. Hence, lncRNA-ATB shows potential for the diagnosis and treatment of GC and is expected to serve as a novel diagnostic and prognostic biomarker and therapeutic target.
| Colorectal cancer
Colorectal cancer (CRC), which affects greater than 1.2 million people annually, is a common disease worldwide, and approximately one-fifth of patients exhibit metastases when diagnosed. CRC patients with metastases typically exhibit a survival rate of less than 5 years.
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As such, the development of sensitive and specific biomarkers for the 
| Lung cancer
| Renal cell carcinoma
Renal cell carcinoma (RCC) is one of the most lethal urologic cancers.
Patients with RCC often present with distant metastases at the time of diagnosis due to the lack of early indicators for detection. 46 As a result, identifying effective biomarkers is essential to not only predict the prognosis of RCC but also to help expand innovative targeted therapies for RCC. suggest that lncRNA-ATB as a biomarker is a potential oncogenic lncRNA in RCC that can identify patients with acute rejection after renal transplantation.
Xiong et al
| Breast cancer
Breast cancer (BC) is the leading reason of cancer deaths in women, and its incidence rates are gradually increasing worldwide. Distant metastasis and drug resistance are major challenges in the treatment of BC. 49 Hence, the development of reliable biomarkers to predict drug responsiveness and tumour progression should be a priority. Shi et al 50 
| Glioma
Glioma is the most lethal primary central nervous system tumour, leading to significant mortality worldwide annually. 51 Ma et al 52 reported
that lncRNA-ATB expression was significantly increased in glioma tissues and cell lines compared with that in normal brain tissues and was associated with poor outcomes in glioma patients. In addition, knocking down lncRNA-ATB inhibited the malignant biological behaviour of glioma cells, including proliferation, colony formation, migration, and invasion. Thus, the discovery of lncRNA-ATB may provide a new direction for targeted glioma treatment.
| Keloid
Keloids, a subgroup of benign skin cancers, result from abnormal wound healing and never regress spontaneously. The treatment of keloids is a particular challenge. 53 Zhu et al 54 demonstrated that lncRNA-ATB expression was significantly increased in both keloid tissues and fibroblasts compared with that in normal skin tissues and fibroblasts, respectively. Thus, lncRNA-ATB might be a promising biomarker for the diagnosis of and a potential target for the treatment of keloids.
| Prostate cancer
Prostate cancer is the most frequently diagnosed malignancy in males worldwide. 25 Xu et al 55 discovered that lncRNA-ATB levels were significantly increased in prostate cancer tissues compared with levels in adjacent nontumour tissues. With regard to clinicopathological parameters, increased lncRNA-ATB levels were closely associated with histological grade, high preoperative prostate specific antigen (PSA) levels, pathological stage, high Gleason score, lymph node metastasis, angiolymphatic invasion and biochemical recurrence. In general, lncRNA-ATB displays advantageous characteristics as a novel biomarker for early diagnosis, prognosis evaluation, and as a therapeutic target in prostate cancer.
| Pancreatic cancer
Pancreatic cancer is the fourth primary cause of cancer-related deaths worldwide and is typically diagnosed at advanced stages as a result of its deep location and atypical symptoms. 56 Unlike the above studies, lncRNA-ATB is downregulated in pancreatic cancer tissues and cell lines compared with in controls. Moreover, low lncRNA-ATB expression was significantly correlated with lymphatic metastasis, neural invasion and clinical stage. Notably, multivariate analysis revealed that decreased lncRNA-ATB expression was an independent predictor of poor prognosis, highlighting lncRNA-ATB as a potential tumour suppressor in pancreatic cancer. 57 Nevertheless, the specific mechanism of lncRNA-ATB in pancreatic cancer needs to be further investigated.
Perhaps, due to differences in tumour tissue origin, extracellular microenvironment, and upstream and downstream regulatory factors, lncRNA-ATB can function not only as an oncogene but also as a tumour suppressor.
| REGULATORY MECHANISMS OF LNCRNA-ATB
Transforming growth factor β (TGF-β) is a multifunctional cytokine that modulates tumourigenesis and progression in part by inducing the epithelial-mesenchymal transition (EMT). 58, 59 lncRNA-ATB, which is activated by TGF-β, enforced zinc finger E-box binding homeobox . 34 In addition, lncRNA-ATB overexpression might act on colon tumorigenesis by decreasing the expression of epithelial markers (eg, E-cadherin and zonula occludens 1) and increasing the expression of mesenchymal markers (eg, ZEB1 and N-cadherin) to promote the EMT. 42 In addition to acting as a ceRNA, lncRNA-ATB can also activate various signalling pathways. Xu et al 55 
| CONCLUSION AND FUTURE PERSPECTIVES
lncRNA-ATB, a well-characterized cancer-related lncRNA, can alter cellular functions such as proliferation, migration and invasion in various human cancers. The mechanisms by which lncRNA-ATB promotes cytotoxic chemotherapy, molecular targeted therapy has the advantages of strong tumour specificity and low systemic toxicity. As a viable drug target, lncRNA-ATB is extraordinarily promising. Ongoing efforts to clarify the underlying mechanisms promise that lncRNA-ATB will ultimately reach the clinic.
